Intranasal formulation for osteoporosis treatment to be withdrawn; new restriction to indication for injectable use in Paget’s disease. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that calcitonin-containing medicines should only be used for short-term treatment, because of evidence that long-term use of these medicines is associated with an increased risk of cancer.

Descargar